Sosei Group (JP:4565) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Nxera Pharma has commenced a Phase 3 clinical trial in South Korea to evaluate its insomnia treatment, daridorexant, following its recent approval in Japan. Insomnia affects a significant portion of South Korea’s population, and this trial aims to provide further efficacy and safety data to secure marketing authorization in the country. The trial underscores Nxera’s commitment to addressing insomnia’s serious health impact and expanding its market reach in Asia.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- A New “Anti-Woke ETF” Takes Aim at Starbucks (NASDAQ:SBUX)
- Ford (NYSE:F) Plans New EV Plant Close to Nickel
- The Gelsinger Post-Mortem Starts at Intel (NASDAQ:INTC)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
